InvestorsHub Logo

poonch1ne

08/04/16 10:26 AM

#72543 RE: JB3729 #72539

Great post, thanks. Will probably win my common sense post of the day and it's only 10:30 AM.

JB3729

08/05/16 10:14 AM

#72647 RE: JB3729 #72539

Why I believe that the 2a trial is benefitting a high % of patients -

7/22/15 - ANAVEX 2-73 showed in 83 percent (10/12) of patients positive cognitive effects during PART A of the study, which consists of a 36-day on-off-on not-yet-optimized dosing regimen to assess bioavailability.

11/9/2015 - In a preliminary interim readout of PART B data, ANAVEX 2-73 improved ADCS-ADL score, a functional measurement, over a period of 12 weeks by +3.21 over baseline, with 11 out of 14 (78.6%) patients improving.